SCHEMBL6476542

SCHEMBL6476542

CCN(CC)c1ccc(CCCc2ccc(N(CC)c3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CNR2 P34972 5/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
NOX1 Q9Y5S8 1/20 0.43
AOC3 Q16853 1/20 0.42
PLK1 P53350 4/20 0.41
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
NFKB1 P19838 2/20 0.40
TP53 P04637 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40
GMNN O75496 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475705 0.91 CNR2 (0.46) MEN1KMT2ASMN1; SMN2L3MBTL1CNR2
SCHEMBL6474913 0.78 MEN1 (0.55) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL6475710 0.76 CLCN2 (0.49) MEN1KMT2ASMN1; SMN2L3MBTL1CNR2
SCHEMBL1668024 0.74 TP53 (0.53) MEN1KMT2ASMN1; SMN2L3MBTL1NPC1
SCHEMBL14174039 0.74 CNR2 (0.67) CNR2AOC3TSHR
SCHEMBL6313104 0.73 ALDH1A1 (0.54) MEN1KMT2AL3MBTL1CNR2AOC3
SCHEMBL6474928 0.73 SIRT1 (0.50) MEN1KMT2ANPC1RAB9ANOX1
SCHEMBL28860869 0.73 TSHR (0.58) MEN1KMT2ASMN1; SMN2L3MBTL1CNR2
Ammonia Solution, Strong SCHEMBL27451904 0.72 TP53 (0.51) MEN1KMT2ASMN1; SMN2L3MBTL1NPC1
SCHEMBL27560780 0.72 ALDH1A1 (0.46) MEN1KMT2ASMN1; SMN2L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885SMN1; SMN2 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.